CONSORT diagram showing the flow of participants through each stage of the DOREPAR randomized trial for the main outcome (change of VAS). by Karel Joineau (21799908)

Subjects:

Demographic and clinical data at baseline. by Karel Joineau (21799908)

Subjects:

Changes in clinical variables. by Karel Joineau (21799908)

Subjects:

Change of functional connectivity in the SMN after intervention. by Karel Joineau (21799908)

Subjects:

Connectivity between the left nucleus accumbens and two clusters. by Karel Joineau (21799908)

Subjects:

Design of the protocol. by Karel Joineau (21799908)

Subjects:

Schema of the reflexology circuit and the stimulated reflex zones. a. by Karel Joineau (21799908)

Subjects:

Trends of incident opioid users, L-TOT users, and L-TOT discontinuers between 2009 and 2013. by Qian Cai (112039)

Subjects:

The yearly numerator, denominator and rate of incident opioid users, L-TOT users and L-TOT discontinuers from 2009 to 2019. by Qian Cai (112039)

Subjects:

Incidence rate ratios of negative binominal regression models for yearly rates of incident opioid users, L-TOT users and L-TOT discontinuers during 2009–2013 and 2015–2019. by Qian Cai (112039)

Subjects:

Demographic, comorbidity, concurrent drug, and opioid characteristics, among L-TOT users and L-TOT discontinuers between 2009–2019. by Qian Cai (112039)

Subjects:

The technical route of the study. by Hongliang Zou (20707270)

Subjects:

Point cloud fusion instance effect. by Hongliang Zou (20707270)

Subjects:

Experimental results in the SubT-MRS dataset. by Hongliang Zou (20707270)

Subjects:

Epac activation increased MYPT phosphorylation via PLC/PKC. by Yoshiki Ohnuki (576298)

Subjects:

Phosphorylation status of myofilament proteins prepared from Epac1TG. by Yoshiki Ohnuki (576298)

Subjects:

Mean liver weight (g) (A), liver weight/body ratio (B), hepatic triglyceride (mg/g) (C) and hepatic steatosis quantification (% area) (D) upon completion of the treatment phase. by Elsie D. Oduor (22521785)

Subjects:

Epac activation with 8CPT-AM induced RLC phosphorylation in the perfused hearts. by Yoshiki Ohnuki (576298)

Subjects:

Epac activation increased RLC phosphorylation via PLC/PKC. by Yoshiki Ohnuki (576298)

Subjects:

TBSS results showing significant AxD and RD changes at baseline and the follow-up. by Sewon Lim (21989785)

“…The decreased diffusivity metrics (AxD and RD) exhibited no statistically significant differences at <i><i>P</i></i> < 0.05 after correcting for multiple comparisons (FWE). …”